PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
PROTHENA CORP PUBLIC LTD CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.48+0.13 (+1.56%)
Close on Oct 19, 2026
- Market cap
- $442.19M
- P/E (TTM)
- –
- Dividend yield
- –
PROTHENA CORP PUBLIC LTD CO revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from license and intellectual property | $50.05M | $50.05M | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $50.00K | $40.05M | 91.8% | +100000.0% |
| Collaboration revenue | $4.48M | $7.89M | $9.63M | $11.74M | $10.29M | $137.89M | $135.11M | $133.30M | $217.20M | $89.20M | $91.32M | $100.93M | 8.2% | -56.5% |
By region
From the segment and revenue-disaggregation notes of Prothena Corp Public's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.